CriticalAntiretroviral, HIV protease inhibitor×Antidepressants. Other antidepressants of herbal origin
Updated · Methodology
Mechanism
St John's wort induces several liver enzymes that metabolise drugs, including the enzyme CYP3A4, and the transporter P-glycoprotein, so the levels and effect of many drugs can fall (St John's wort summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS; St John's wort herbal monograph, European Medicines Agency, EMA). The liver breaks down atazanavir through CYP3A4. According to the atazanavir documents, St John's wort can be expected to lower atazanavir levels markedly, so human immunodeficiency virus (HIV) treatment may lose its effect and the virus may become resistant (atazanavir SmPC, EMA, and atazanavir label, US Food and Drug Administration, FDA). Atazanavir boosted with cobicistat is even more sensitive to this induction, and St John's wort lowers the levels of both components (atazanavir/cobicistat SmPC, EMA). After St John's wort is stopped, the increased enzyme activity returns to normal within 1 week (St John's wort herbal monograph, EMA).
Symptoms
The combination itself usually causes no symptoms: atazanavir loses its effect, the human immunodeficiency virus (HIV) viral load rises, and the virus may become resistant to treatment (atazanavir summary of product characteristics, SmPC, European Medicines Agency, EMA, and atazanavir label, US Food and Drug Administration, FDA). A rising viral load shows only on blood tests. The Spanish SmPC of a St John's wort product also lists a fall in levels with possible loss of HIV suppression for protease inhibitors, atazanavir among them (St John's wort SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS).
Management
The combination is contraindicated. The atazanavir documents contraindicate any products containing St John's wort, both with and without ritonavir (atazanavir and atazanavir/cobicistat summaries of product characteristics, SmPCs, European Medicines Agency, EMA; atazanavir SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS; atazanavir label, US Food and Drug Administration, FDA). The contraindication is the same from the St John's wort side: the Spanish St John's wort product must not be taken with protease inhibitors, and its interaction table names atazanavir (St John's wort SmPC, AEMPS). The authorisation of this product has been suspended since June 2026, and there is no other current Spanish St John's wort SmPC. The EMA monograph contraindicates St John's wort with protease inhibitors for well-established use products, and for traditional use products when the daily hyperforin dose exceeds 1 mg (St John's wort herbal monograph, EMA). The atazanavir documents make no such dose exception. Stop St John's wort before starting atazanavir (atazanavir SmPC, EMA, and FDA label). The increased enzyme activity returns to normal within 1 week after St John's wort is stopped (St John's wort herbal monograph, EMA), but the atazanavir documents give no exact interval before atazanavir is started.
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Reyataz (atazanavir) prescribing information (2024)– DailyMed setid 165cff62-b284-4a27-a65d-9ec8a5bfcdd8, revisión 12/2024, secciones 4 y 7.3
- EMA: Ficha técnica: Atazanavir, Reyataz (EU/1/03/267), sección 4.3 (2026)– EMA, Reyataz 300 mg cápsulas (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 03267008, consultada 10/2026, sin fecha de revisión en CIMA, secciones 4.2, 4.3, 4.4 y 4.5
- EMA: Ficha técnica: Atazanavir/cobicistat, Evotaz (EU/1/15/1025), sección 4.3 (2026)– EMA, Evotaz 300 mg/150 mg comprimidos (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 1151025001, consultada 10/2026, sin fecha de revisión en CIMA, secciones 4.3 y 4.5
- AEMPS: Ficha técnica: Atazanavir (nº registro 84068), sección 4.3 (2024)– AEMPS, CIMA, Atazanavir Stada 300 mg cápsulas duras EFG, nº registro 84068, documento 05/2024 (fecha de revisión del texto 02/2024), secciones 4.3 y 4.5
- AEMPS: Ficha técnica: Hipérico (Hypericum perforatum) (nº registro 79963), secciones 4.3 y 4.5 (2025)– AEMPS, CIMA, Hipérico Arkopharma cápsulas duras, nº registro 79963, documento 11/2025 (fecha de revisión del texto 09/2016), secciones 4.3, 4.4 y 4.5; autorización suspendida desde el 11.06.2026, única ficha técnica de hipérico no revocada en CIMA
- EMA: European Union herbal monograph on Hypericum perforatum L., herba – Revision 1 (EMA/HMPC/7695/2021) (2022)– EMA, Committee on Herbal Medicinal Products (HMPC), European Union herbal monograph on Hypericum perforatum L., herba, Final – Revision 1, EMA/HMPC/7695/2021, 23.11.2022 (publicada 22.02.2023), secciones 4.1, 4.3 y 4.5